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Abstract
Background: The aims of this study were to determine the documentation of
pharmacotherapy optimization goals in the discharge letters of patients with
the principal diagnosis of chronic heart failure.
Methods: A retrospective practice audit of 212 patients discharged to the care
of their local general practitioner from general medical units of a large tertiary
hospital. Details of recommendations regarding ongoing pharmacological and
non-pharmacological management were reviewed. The doses of medications
on discharge were noted and whether they met current guidelines recom-
mending titration of angiotensin-converting enzyme inhibitors and beta-
blockers. Ongoing arrangements for specialist follow up were also reviewed.
Results: Themean age of patients whose letters were reviewedwas 78.4 years
(standard deviation  8.6); 50% were men. Patients had an overall median of
six comorbidities and eight regular medications on discharge. Mean length of
stay for each admission was 6 days. Discharge letters were posted a median
of 4 days after discharge, with 25% not posted at 10 days. No discharge letter
was sent in 9.4% (20) of the cases. Only six (2.8%) letters had any recom-
mendations regarding future titration of angiotensin-converting enzyme
inhibitors and 6.6% (14) for beta-blockers. Recommendations for future
non-pharmacological management, for example, diuretic action plans, regular
weightmonitoring and exercise planswere not found in the letters in this audit.
Conclusion: Hospital discharge is an opportunity to communicate manage-
ment plans for treatment optimization effectively, and while this opportunity
is spurned, implementation gaps in the management of cardiac failure will
probably remain.
Introduction
Chronic heart failure (CHF), which affects more than
300 000 Australians, is a common and serious condition,
with a 5-year mortality rate of 50%.1,2 Fortunately, over the
last 10 years, the prognosis has improved and clear survival
benefit has been shown with the use of angiotensin-
converting enzyme inhibitors (ACEI), beta-blockers and
non-pharmacological therapies.3 However, there continue
to be significant gaps between best and actual practice, both
in hospital and community settings.3 CHF patients have
a significant rate of readmission, which can be lessenedwith
adequate post-discharge management.4
A previous audit by our group has found thatmore than
90% of eligible patients with CHF were prescribed ACE
inhibitors on discharge.5 In contrast, there were several
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system barriers to the up-titration ACE inhibitors and the
addition of beta-blocker therapy identified during the
admission.6–9 These barriers included shorter hospital
length of stay, uncertainty regarding drug history and
previous medication experiences and the fact that most
patients do not have clinically stable heart failure during
their inpatient presentation.8–10 For most CHF patients,
hospitalization can be the beginning of medication opti-
mization, which requires continuation after discharge.7
Although CHF is a significant proportion of hospital
admissions, general practitioners (GPs) manage this con-
dition less frequently.11 Perceived barriers to the imple-
mentation of best practice guidelines for the management
of CHF in primary care include inadequate provision of
documentation from medical specialists, especially for
recently hospitalized patients, as well as a lack of infor-
mation and awareness about the dosing of ACE inhibitor
and beta-blockers.8,9
Unfortunately, even with a strong evidence base, only
8–11% of all CHF patients access ‘specialized’ multidisci-
plinary CHFmanagement.6 However, a hospital admission
within this group of patients does provide an opportunity
for specialist review and follow-on communication to the
GP on a recommended treatment plan and future goals. To
date, there has been a paucity of published work to show
howoften this occurs in practice. The aim of this studywas
to determine the level of documentation of management
plans and pharmacotherapy treatment goals, in CHF
patients discharged from a tertiary referral hospital to the
care of their GP, who would not be followed up by a
specialist heart failure programme.
Methods
A retrospective practice audit was conducted within the
general medical units of the Royal Adelaide Hospital
(RAH), a 650-bed tertiary referral institution located in
the city of Adelaide, South Australia.
Inclusion criteria
All patients discharged home to metropolitan Adelaide
(post codes 5000–5199) with International Classification
of Diseases-10 codes relating to a principal diagnosis of
CHF including ‘congestive heart failure’, ‘cardiomyo-
pathy unspecified’, ‘ischaemic cardiomyopathy’, ‘left
ventricular failure’, ‘dilated cardiomyopathy’ and ‘acute
pulmonary oedema’ in the 12-month period commenc-
ing 1 January 2005 to 1 January 2006. These codes have
previously been shown to have a high specificity for the
Framingham criteria diagnosis of CHF.5 During this
period there was no specialized heart failure programme
available at the RAH.
Exclusion criteria
Patients discharged to nursing homes, other hospitals or
hospices, those deemed to be palliative for reasons other
than cardiac failure and patients with severe dementia
were excluded.
As part of the standard patient care process, the hospital
posts a discharge summary, including a medication list to
the patient’s GP, which is available electronically. Each of
these electronic summaries was reviewed by the research
team to assess: the dosage of ACE inhibitor, beta-blocker
and diureticmedication comparedwith the recommended
dosages, the presence of recommendations for ongoing
pharmacological and non-pharmacological manage-
ment, arrangements for specialist follow up, total
number of comorbidities and regular medications pre-
scribed on discharge.12–14 For each medication, docu-
mentation of contraindications was also sought within
the electronic discharge summary. For ACE inhibitors,
these included the presence of bilateral renal artery
stenosis, severe renal failure, hypotension, history of
angioedema or previous documented intolerance. For
beta-blockers these included hypotension, severe brady-
cardia or heart block, reversible airway disease or severe
chronic obstructive airway disease. Auditmaker (The
Australian Centre for Evidence-Based Clinical Practice,
Adelaide, South Australia) was used as the clinical audit
tool.15
In our assessment of the prescribed medications, we
took a generous approach towards the choice of drugs in
each class. Beta-blockers not specifically indicated for
CHF (atenolol and standard formulation of metoprolol)
were deemed to be acceptable, as many patients have
heart failure with preserved systolic function and these
agents may be used for rate control and improved dias-
tolic filling.14 As the discharge summaries did not have
details of certain clinical parameters, which may have
limited drug dosage maximization, for example, blood
pressure, heart rate, divided the drug doses as being less
than half of the maximal dosage, which are usually start-
ing doses, and more than or equal to half of maximal
dosage, suggesting that some dosage maximization had
already occurred.
Analysis
Data analysis and statistical measures were carried out
using MICROSOFT EXCEL 2003 and MICROSOFT ACCESS
2003 (Microsoft Corporation, Seattle, Washington, USA).
Descriptive statistics describing demographics and audit
outcomes are presented as proportions or means,
medians and standard derivations with 95% confidence
intervals.
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Results
During the study period between 1 January 2005 and 1
January 2006, there were 351 admissions with the prin-
cipal diagnosis of CHF. Of these there were 27 deaths
during admission, 31 patients were discharged to other
hospitals and 55 to residential care facilities. Of the
remaining 238 patients, 22 involved discharges outside of
the metropolitan area and 4 patients had either advanced
dementia or were palliative resulting in a total of 212
discharges, which were reviewed. The characteristics of
these patients are presented in Table 1. Patients were
elderly comorbid group, which was prescribed a median
of eight regular medications on discharge. Most patients
(60%) were followed up exclusively by their GPs with no
further specialist appointments. Discharge letters were
sent a median of 4 days after discharge with 25% of GPs
being sent the information 10 or more days after dis-
charge. No discharge letter was sent in 9.4% (20) of
cases.
As can be seen from Table 2 only six of the 212 dis-
charge letters (2.8%) had documented recommenda-
tions regarding future titration of ACE inhibitors. If the
patients who may not have benefited from up-titration
are excluded from this group (i.e. those with docu-
mented contraindication or those already prescribed
greater than half the recommended maximum dosage)
then approximately 5.6% (eight) patients had a docu-
mented dosage recommendation in their discharge
letter. Similarly, only 6.6% (14) of all letters had infor-
mation regarding the future aims of the beta-blocker
therapy (Table 2). Again, if patients who may not have
benefited from up-titration of their beta-blockers are
excluded from this group, notation of future manage-
ment was recorded in only 10% of discharge letters
(Table 2). Only six letters (2.8%) had information on
future dose alterations of diuretics. Recommendations
for non-pharmacological management, for example,
diuretic action plans, regular weight monitoring and
exercise plans were not found in any letter reviewed in
this audit.16
Discussion
This review of discharge communication is, to the best of
our knowledge only the second project to examine this
issue specifically in relation to CHF.
A similar study, carried out by Raval et al. also
stressed significant deficiencies in discharge documenta-
tion.17 Van Walraven et al. found that the provision of a
discharge letter decreased the rate of readmission
among patients admitted to hospital with acute me-
dical illnesses.18 Inadequate documentation has been
Table 1 Characteristics of patients reviewed
Characteristics Mean, n = 212
Age in years (mean and SD) 78.4 years (SD  8.6)
Sex n (%)
Male 105 (49.5)
Female 107 (50.5)
Length of stay – median (days) 6 days
Mean no. comorbidities 5.43 (SD  2.4)
No. days from discharge to
posting of information to GP
7.75 (SD  12.03),
median 4 days
Discharge information sent >10 days
after discharge (%)
53 (25.0)
GP, general practitioner; SD, standard deviation.
Table 2 Documentation of ACE inhibitor/angiotensin II antagonist and
beta-blocker prescription and dosage in discharge summary/letters
Documentation of ACE inhibitor/
angiotensin II antagonist prescription and
dosage within discharge summary letters
n (%) (95%CI),
n = 212
Total prescribed ACEI 156 (73.5%)
High dose (dosage at 50% of
maximum dose†)
55 (25.9) (20–32)
Low dose with recommendations for
up-titration (<50% of maximum
dosage)
8 (3.8) (2–7)
Low dose without recommendation
for up-titration (<50% of
maximum dosage)
93 (43.9) (37–51)
Drug not prescribed with
documented contraindication†
13 (6.1) (4–10)
Drug not prescribed without
explanation
23 (10.8) (7–16)
Discharge summary letter never written 20 (9.4) (6–14)
Documentation of beta-blocker prescription and dosage in discharge
letters
Total prescribed beta-blocker 93 (43.6%)
High dose (dosage at 50% of
maximum dose†)
33 (16.0) (11–21)
Low dose with recommendations
for up-titration (<50% dosage)
7 (3.3) (2–7)
Low dose without recommendations
for up-titration (<50% of
maximum dosage)
53 (25.0) (19–31)
Drug not prescribed with
documented contraindication†
32 (15.1) (11–20)
Not prescribed with recommendation
for future prescription
7 (3.3) (2–7)
Drug not prescribed without
explanation
54 (25.5) (20–31)
Letter not written 20 (9.4) (6–14)
Other, for example, prescribed sotalol
for arrhythmia
5 (2.4) (1–5)
†No dosage recommendation required. 95%CI, ninety-five per cent confi-
dence interval; ACEI, angiotensin-converting enzyme inhibitors.
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identified as a barrier to the implementation of best
practice guidelines for CHF5 and as ideal management
of CHF reduces mortality and morbidity,3 it is possible
that improving discharge communication could improve
outcomes in patients with CHF.15 Overall, our review
showed that the quality of the documentation of
recommendations for pharmacological and non-
pharmacological management was very poor. In par-
ticular, very few letters (<15%) outlined a plan of
management for the future dose titration of any of the
heart failure medications. The prescription of ACE
inhibitors and beta-blockers, both of which have proven
benefit in reducing heart failure mortality and morbid-
ity, was not in keeping with the current best practice
guidelines13 and 70% of patients were receiving an
ACE inhibitor and 50% were receiving a beta-blocker.
This rate of prescription was, however, similar to those
reported from the CASE study (19) (ACEI 58% and
beta-blocker 14%) and The EuroHeart Survey (ACEI
61.8% and beta-blocker 36.9%) (14).
Given the fact that patients were admitted with de-
compensated heart failure (in the context of numerous
other comorbidities), this observation is perhaps not sur-
prising. However, given that most were followed up by
their GPs and advice regarding this optimization was not
communicated in the discharge letter, it is unlikely that
this implementation gap will be bridged. Furthermore,
the discharge letter is usually the only routine tool for
communication with GPs. As CHF is a common condi-
tion within medical services of a large hospitals, but
constitutes only a small percentage (2.9%) of patients
seen by GPs,1,19 it may be unreasonable to expect GPs to
initiate optimal CHF management without specialist
guidance.9,13,19 The discharge letter may be a small
window of opportunity for education on the future treat-
ment and drug optimization requirements in this group
of complex patients.20
The reasons for our findings are probably multifactorial
and their detailed investigation is beyond the scope of
this paper. At our institution, the discharge summary is
completed by the intern, who is the most junior member
of the treating team, and the one who is least likely to
appreciate the ongoing management requirements of the
patient. Our institution also does not have a chronic
disease management service and hence the chronic man-
agement of the patients is frequently not considered
during their inpatient management.
In light of our results we would recommend that
patients with chronic diseases, such as CHF, who have
acute hospital admissions and specialist contact punctu-
ating their disease journey, have standardized recom-
mendations for future management as an obligatory
component of their discharge planning process.21
Limitations
This review was conducted in only one institution and
reviewed information only from discharge letters. The
possible reasons why the discharge letters failed to
convey adequate documentation are numerous and we
could not assess other communications such as telephone
contact. The maximal doses of the medications for each
patient should ideally have been assessed by reviewing
the patient’s case notes to assess factors that would have
limited further dose increases. As this information was
not available in the discharge letters, we arbitrarily chose
a cut-off of 50% of the maximum recommended dosage
for each drug, to indicate that an adequate dose had been
prescribed. It is possible that this approach overestimated
the number of patients who would have benefited from
recommendations regarding dosage increases in their dis-
charge letter. However, given the very poor level of docu-
mentation of dosage recommendation, this is unlikely to
have changed the overall conclusion of the study.
The strengths of the study were that the audit could
evaluate a large number of discharge letters for an entire
year across five different medical units of a large metro-
politan hospital, hence sampling bias was eliminated.
Conclusion
The findings of this study suggest that even when there
are standardized approaches for discharge communica-
tion, for example, software for electronic discharge
letters, important management and treatment goals are
not included. This would suggest that other structured
approaches are required to implement a more satisfactory
transition for patients from the hospital to the commu-
nity, especially for patients with chronic diseases.
Hospital discharge is an opportunity to communicate
effectively a management plan for treatment optimiza-
tion to the patient’s principal clinician, and although
this opportunity is spurned, implementation gaps in the
management of CHF will probably remain.
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